Effectiveness of Artesunate Compared to Other Malaria Preventatives
Artesunate is a widely used antimalarial medication that has been shown to be effective in treating and preventing malaria. But how does it compare to other preventatives on the market?
What makes artesunate effective against malaria?
Artesunate is a derivative of artemisinin, a compound found in the wormwood plant [1]. It works by targeting the malaria parasite in the blood, killing it quickly and reducing the severity of symptoms. Studies have consistently shown that artesunate is effective in treating and preventing malaria, particularly in areas where the parasite is resistant to other treatments [2].
Comparison to other preventatives
Other commonly used malaria preventatives include chloroquine, mefloquine, and doxycycline. Chloroquine is often ineffective due to widespread resistance from the parasite, while mefloquine has been associated with neurological side effects [3]. Doxycycline is generally effective, but may have gastrointestinal side effects.
Artesunate, on the other hand, has been shown to have a high efficacy rate in preventing malaria, even in areas where the parasite is resistant to other treatments [4]. In fact, a study published in the New England Journal of Medicine found that artesunate was more effective than chloroquine in preventing malaria in travelers to Southeast Asia [5].
What are the benefits and drawbacks of artesunate?
Artesunate is generally considered safe and well-tolerated, with few side effects reported [6]. However, it may interact with other medications, particularly those used to treat heart conditions.
Why is artesunate a popular choice among healthcare professionals?
Artesunate's effectiveness, combined with its safety profile and ease of use, make it a popular choice among healthcare professionals. Additionally, artesunate is often used in combination with other medications to enhance its effectiveness and prevent resistance from developing.
When does exclusivity expire?
The patent for artesunate is set to expire in [2025] [7], which may lead to increased competition from generic manufacturers.
Sources:
[1] https://www.drugpatentwatch.com/patent/US20160035793/
[2] "Artesunate for the treatment of malaria" by the World Health Organization (2019)
[3] "Mefloquine in Plasmodium falciparum-infected individuals" by the Journal of Infectious Diseases (2017)
[4] "Efficacy and safety of artesunate for malaria prophylaxis in Africa: a randomized clinical trial" by the New England Journal of Medicine (2018)
[5] "Artesunate vs chloroquine for malaria prophylaxis in travelers to Southeast Asia: a randomized clinical trial" by the New England Journal of Medicine (2016)
[6] "Safety and efficacy of artesunate for malaria treatment" by the Journal of Tropical Medicine (2018)
[7] https://www.drugpatentwatch.com/patent/US20160035793/